Revolution Medicines, Inc.

David E Wildes

Mallika Singh

Elena S Koltun

Adrian L Gill

Naing N Aay

Yang Liu

James Joseph Cregg

John Edward Knox, Jr

Andreas Buckl

G Leslie Burnett

Meghan A Rice

Christopher Schulze

Jacqueline Smith

Stephen Kelsey

Mark A Goldsmith

Robert J Nichols

Bianca Jennifer Lee

The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Ras inhibitors

The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

SHP2 inhibitor compositions and methods for treating cancer

Growing community of inventors

Redwood City, CA, United States of America

David E Wildes